Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company's common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亚诺瓦托，2024年11月20日 (环球新闻社) -- ultragenyx pharmaceutical 公司（NASDAQ: RARE）是一家专注于罕见和超罕见疾病新疗法开发和商业化的生物制药公司，今天报告称，公司董事会薪酬委员会批准向公司13名新任非执行官授予20,820股限制性股票单位，这些奖励授予在ultragenyx就业诱导计划下批准，并于2024年11月16日授予，作为新员工按照Nasdaq上市规则5635(c)(4)与ultragenyx签订就业协议的诱因重要素材。
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
限制性股票实行四年分期归属，股票的25%将在授予日期的每个周年之日授予，但前提是该员工在归属日期继续为公司工作。
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
关于Ultragenyx Pharmaceutical Inc.
Ultragenyx是一家生物制药公司，致力于为罕见的和极其罕见的遗传病提供新型治疗产品。该公司已构建了一个多样化的批准治疗方案和产品候选组合，旨在解决存在高需求和明确生物学治疗的疾病，而通常没有治疗相关潜在疾病的批准治疗方案。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
该公司由一支有丰富罕见病治疗药物开发和商业化经验的管理团队领导。Ultragenyx 的策略基于及时高效的药品研发，旨在以最大的紧迫性向患者提供安全有效的治疗。
For more information on Ultragenyx, please visit the company's website at: .
有关Ultragenyx的更多信息，请访问该公司的网站。
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
联系超凡妥
投资者和媒体
Joshua Higa
（415）475-6370
